A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients | NYU Langone Health

Go Back to All Clinical Trials

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Wnt-driven Medulloblastoma
Age: Between 3 years - 21 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patients who are in classic (medullablastoma) MB of the WNT-subgroup and must be newly diagnosed, confirming by rapid central pathology and molecular screening review on APEC14B1. 2) Patient must have negative lumbar CSF cytology.

You may not be eligible for this study if the following are true:

1) Patients who have metastatic diseases. 2) Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology.